Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. - Wikidata - awgldk - TriplyDB

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

http://www.wikidata.org/entity/Q48863873

about

Adult brain cancer in the U.S. black population: a Surveillance, Epidemiology, and End Results (SEER) analysis of incidence, survival, and trends Personalized characterization of diseases using sample-specific networks Identification of candidate drugs for the treatment of metastatic osteosarcoma through a subpathway analysis method.Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis Dissecting dysfunctional crosstalk pathways regulated by miRNAs during glioma progression.p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment.NDRG4 hypermethylation is a potential biomarker for diagnosis and prognosis of gastric cancer in Chinese population.Mutant p53 in cancer: new functions and therapeutic opportunities.Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.Protein Phosphatase Magnesium-Dependent 1δ (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodenroglial Tumors.Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp.Natural products: a hope for glioblastoma patients.

P2860

Q28393814-215B4C41-E03F-4FC1-A60A-D4084A3C0689 Q28586781-88D13542-36DB-4708-8009-06EF3A7539A4 Q33751305-968DD1F1-EF72-46B7-B822-F3112E80D907 Q35679476-3347F703-CB37-4DC8-8080-C0C0C8FEC595 Q37295490-CA7618A5-D7B8-4B47-AFC2-200D2E65ACB6 Q37468744-F82222F0-655C-4D6A-8D42-2A518A17CA65 Q37702670-6E20CCE0-3CCC-430F-A962-C9BC92C8DF80 Q38197826-AD71C896-35BB-4471-8DCD-2F9CE4D38754 Q38601004-91CC1A43-57D4-4FD9-B082-087521183B05 Q38751430-F7EC51D9-DF6E-486C-9CA0-61619D4D4614 Q38846785-1D07F3F9-2027-4E17-A167-A3C752FA8974 Q41460271-8D2DA2AB-57D3-4FF3-AF70-C10E1389F1B0 Q47339574-7A715A36-8507-48C6-8935-9569B9B9D807 Q47631527-03937BCB-98EF-464D-B9A6-6B2CA840CCBC Q47773621-3473DCD3-E288-4611-8690-0323E5D1C7C5 Q48112435-E61182DA-27E1-46C5-AA27-8488450E95C8 Q55445418-7378503A-986B-487E-8AAC-683EF6EDFF6E

P2860

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

http://www.wikidata.org/entity/Q48863873

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

@en

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

@nl

type

label

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

@en

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

@nl

prefLabel

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

@en

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

@nl

P1433

Q48863873-2D852E7D-FBD4-46B6-8B4D-3A57872AAFDC

P1476

Q48863873-4D2B543D-1836-45AB-957C-C1080C246272

P2093

Q48863873-085620AE-57FD-4EE0-9D49-0FF003B76901

Q48863873-09489789-3A01-40EC-AA82-7971304D0FE4

Q48863873-0E6D688B-8B38-46C6-BC79-C3592F4C1D51

Q48863873-3E69469C-E6D9-4ECD-ABF9-92C13A3F6AB6

Q48863873-8292C1F7-82FB-46C7-A0ED-EB75A927AA7E

Q48863873-E38B0E72-9B63-4A93-8A30-13C12101AAD8

P2860

Q48863873-23DC3F5F-3ABE-4818-BFBA-FB3FF5C4DC81

Q48863873-459262CD-68D2-4887-B611-63FBA13C88F5

Q48863873-554F4CC0-CF70-45A9-8998-50FB9DFBDD84

Q48863873-5C0F8E4F-3363-4A62-924E-7483E314FFAB

Q48863873-60E3D40B-DE8F-4364-A64D-674A99788D6F

Q48863873-69AD75A6-3240-4305-ABA8-243EBF0C3AA6

Q48863873-7DE3A73E-0631-4C4E-9BE8-34443442EC7D

Q48863873-93284127-E0B5-4353-B475-DA0F962A6102

Q48863873-AC5E487F-1514-4CC9-A7A0-34DFEC3D7141

Q48863873-B0091F17-ECC1-4B35-B108-DBC8762EDD24

P2888

Q48863873-9CF4AB23-06CA-492D-86D5-36F35117B355

P304

Q48863873-FD955479-9FFB-49D6-8E7A-D56DBFEB0225

P31

Q48863873-4EEEC5F5-664B-4582-897C-5535E8147732

P356

Q48863873-61D83EF8-E871-49D4-832B-00CB8C3468C3

P433

Q48863873-053F8C02-029C-4F0E-B87F-921B60743BDC

P478

Q48863873-33697B65-1B82-4E28-A87C-DB59740AB4FF

P577

Q48863873-F6F9F64B-233E-403C-90B1-7DDB7AA66AE0

P6179

Q48863873-ED689B83-6B94-4003-AA5C-B34C88EFA4BA

P698

Q48863873-15C3D6D7-B0EE-4EFC-9056-3AF480E0D421

P356

S10434-013-3380-0

P1433

Annals of Surgical Oncology

P1476

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

@en

P2093

Chao You

http://www.w3.org/2001/XMLSchema#string

Jin-Ping Liu

http://www.w3.org/2001/XMLSchema#string

Jin-Xiu Chen

http://www.w3.org/2001/XMLSchema#string

Qing Mao

http://www.w3.org/2001/XMLSchema#string

Xiang Wang

http://www.w3.org/2001/XMLSchema#string

Yan-Hui Liu

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.

Reactivation of mutant p53: molecular mechanisms and therapeutic potential.

O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells.

p53 protein accumulation and gene mutations in human glioma cell lines.

p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis.

P2888

s10434-013-3380-0

P304

1337-1344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-013-3380-0

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011698050

http://www.w3.org/2001/XMLSchema#string

P698

24248532

http://www.w3.org/2001/XMLSchema#string